A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)

Inclusion Criteria: 1. Patients with type 2 diabetes (T2DM) WHO meet the diagnostic criteria for diabetes issued by the World Health Organization (WHO) in 1999; 2. Male or female patients aged ≥18, ≤70 years; 3. BMI≥18.5 Kg/m2, \< 35 Kg/m2; 4. Hemoglobin a1C (HbA1C) ≥7.5%; ≤10.5%; 5. Triglyceride ≤500 mg /dL (5.65 mmol/L) (if the researchers judge that the transient increase caused by diet, etc., can be repeated detection) 6. Total cholesterol (TC) ≤250mg/dl (6.45mmol/L) 7. T2DM patients who are taking one or two kinds of oral hypoglycemic drugs with fixed dose ≥2 months and uncontrolled blood glucose. 8. Voluntarily sign informed consent and agree to enter the trial group. Exclusion Criteria: 1. Type 1 diabetes or other specific type of diabetes 2. Fasting blood glucose (FPG) \> 13.3 mmol/L (240 mg/dL); 3. Triglyceride (TG) \> 500 mg /dL (5.65 mmol/L); 4. Total cholesterol (TC) \&gt; 250mg/dl (\&gt; 6.45mmol/L); 5. Refractory hypertension \[that is, on the basis of improving the lifestyle, the blood pressure is still not up to standard after 1 month of applying a reasonably tolerable amount of 3 or more antihypertensive drugs (including diuretics), or the blood pressure can be effectively controlled by taking 4 or more antihypertensive drugs; 6. Taking fibrates, statins, thiazolidinediones, insulin drugs; 7. A clear diagnosis of severe osteoporosis or any other known bone disease; 8. A history of diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome, lactic acidosis and other acute complications of diabetes; 9. Severe microvascular complications (proliferative retinopathy; Urinary albumin/creatinine ratio \&gt; 300 mg/g; Marked peripheral neuropathy, etc.); 10. The New York Heart Association (NYHA) defines congestive heart failure as grade III or IV; 11. Significant liver and kidney dysfunction and systemic disease (significant liver dysfunction is defined as AST\&gt; 2.5 times the upper limit of normal and/or ALT\&gt; 2.5 times the upper limit of normal and/or total bilirubin \&gt; 1.5 times the upper limit of normal value; Renal dysfunction was defined as moderate to severe renal insufficiency (eGFR\&lt;60 ml/ (min\*1.73m2)); 12. Pregnant or lactating women, women of childbearing age who are unable or unwilling to take adequate contraception; 13. Participating in a clinical trial of another drug or medical device in or within 3 months prior to screening; 14. The investigator considers it inappropriate to participate in this clinical trial.